Cardlytics, Inc. (NASDAQ:CDLX) COO Sells $278,884.56 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) COO Amit Gupta sold 23,416 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $11.91, for a total value of $278,884.56. Following the completion of the transaction, the chief operating officer now directly owns 122,676 shares of the company’s stock, valued at $1,461,071.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cardlytics Stock Performance

NASDAQ CDLX traded down $0.85 on Wednesday, hitting $11.52. 652,591 shares of the stock traded hands, compared to its average volume of 1,533,442. The business’s fifty day moving average is $11.10 and its two-hundred day moving average is $9.64. Cardlytics, Inc. has a 12 month low of $4.94 and a 12 month high of $20.52. The firm has a market capitalization of $554.96 million, a price-to-earnings ratio of -3.33 and a beta of 1.44. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.31 and a current ratio of 1.31.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.14) earnings per share for the quarter. Cardlytics had a negative net margin of 43.56% and a negative return on equity of 25.38%. The firm had revenue of $89.17 million for the quarter.

Hedge Funds Weigh In On Cardlytics

A number of large investors have recently made changes to their positions in CDLX. Invesco Ltd. boosted its holdings in shares of Cardlytics by 538.1% in the third quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock worth $13,253,000 after acquiring an additional 677,354 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of Cardlytics in the third quarter worth $5,258,000. Vanguard Group Inc. boosted its holdings in shares of Cardlytics by 13.0% in the third quarter. Vanguard Group Inc. now owns 2,011,705 shares of the company’s stock worth $33,193,000 after acquiring an additional 231,303 shares during the period. EAM Investors LLC bought a new position in shares of Cardlytics in the third quarter worth $2,758,000. Finally, General Equity Holdings LP boosted its holdings in shares of Cardlytics by 31.0% in the fourth quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock worth $5,748,000 after acquiring an additional 147,843 shares during the period. 68.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CDLX. Craig Hallum raised Cardlytics from a “hold” rating to a “buy” rating and upped their target price for the company from $10.00 to $18.00 in a report on Friday, March 15th. Needham & Company LLC upped their target price on Cardlytics from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. Finally, Lake Street Capital upped their target price on Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday, March 15th.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.